199 related articles for article (PubMed ID: 30636579)
1. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
3. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T
Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
[TBL] [Abstract][Full Text] [Related]
6. The role of HGF/MET in liver cancer.
Gupta G; Al-Malki WH; Kazmi I; Thangavelu L; Gupta PK; Jha NK; Prasher P; Singh SK; Dua K
Future Med Chem; 2021 Nov; 13(21):1829-1832. PubMed ID: 34569818
[No Abstract] [Full Text] [Related]
7. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
8. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
9. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
10. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
12. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
13. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats.
Tan XG; Yang ZL
Hepatobiliary Pancreat Dis Int; 2010 Dec; 9(6):639-44. PubMed ID: 21134835
[TBL] [Abstract][Full Text] [Related]
14. C-MET inhibitors in the treatment of lung cancer.
Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
[TBL] [Abstract][Full Text] [Related]
15. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.
Aliebrahimi S; Kouhsari SM; Arab SS; Shadboorestan A; Ostad SN
Biomed Pharmacother; 2018 Oct; 106():1527-1536. PubMed ID: 30119228
[TBL] [Abstract][Full Text] [Related]
16. Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271944
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
18. Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway.
Yasui T; Ohuchida K; Zhao M; Onimaru M; Egami T; Fujita H; Ohtsuka T; Mizumoto K; Tanaka M
Cancer Sci; 2011 Feb; 102(2):484-91. PubMed ID: 21105966
[TBL] [Abstract][Full Text] [Related]
19. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
20. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.
Delitto D; Vertes-George E; Hughes SJ; Behrns KE; Trevino JG
World J Gastroenterol; 2014 Jul; 20(26):8458-70. PubMed ID: 25024602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]